Martin Lackmann 26th Lorne Cancer Conference 2014

Martin Lackmann

A/Professor Martin Lackmann, Protein Interaction & Cancer Research Laboratory, Department of Biochemistry & Molecular Biology, Monash University Martin Lackmann trained as a molecular cell biologist at the University of Hamburg, Germany, and was awarded his PhD in Biochemistry from the University of Sydney. Following postdoctoral positions at the Ludwig Institutue for Cancer Research and the Walter and Eliza Hall Institute of Medical Research in Melbourne, Martin established integrated basic and translational cancer research programs in target discovery and antibody therapeutics development at Monash University. The research in his laboratory focusses on structure, function and activation mechanisms of oncogenic receptor tyrosine kinases, and is published in highly-cited manuscripts in leading journals, including Cell, Nature, Nature Neuroscience, PLoS Biology, J. Cell Biology and PNAS. Martin is inventor on a range of patents in areas of cytokines and receptor tyorsine kinases, therapeutic and diagnostic antibodies. During the past 10 years he has advanced therapeutic antibodies from discovery through to pre-clinical validation and licensing into clinical development. Of these, the anti-EphA3 antibody, KB004, is currently undergoing clinical trials in haematopoietic and solid tumours.